2. Academic Validation
  3. Immunogenic cell death in cancer: concept and therapeutic implications

Immunogenic cell death in cancer: concept and therapeutic implications

  • J Transl Med. 2023 Mar 2;21(1):162. doi: 10.1186/s12967-023-04017-6.
Lorenzo Galluzzi 1 2 3,  Oliver Kepp 4,  Erik Hett 5,  Guido Kroemer 4 6 7,  Francesco M Marincola 8
Affiliations

Affiliations

  • 1 Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. [email protected].
  • 2 Sandra and Edward Meyer Cancer Center, New York, NY, USA. [email protected].
  • 3 Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA. [email protected].
  • 4 Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.
  • 5 Sonata Therapeutics, Boston, MA, USA.
  • 6 Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Institut Universitaire de France, Sorbonne Université, Inserm U1138, Paris, France.
  • 7 Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
  • 8 Kite Pharma Inc, Santa Monica, CA, USA. [email protected].
PMID: 36864446 DOI: 10.1186/s12967-023-04017-6
Abstract

Mammalian cells responding to specific perturbations of homeostasis can undergo a regulated variant of cell death that elicits adaptive immune responses. As immunogenic cell death (ICD) can only occur in a precise cellular and organismal context, it should be conceptually differentiated from instances of immunostimulation or inflammatory responses that do not mechanistically depend on cellular demise. Here, we critically discuss key conceptual and mechanistic aspects of ICD and its implications for Cancer (immuno)therapy.

Keywords

Antigenicity; CAR T cells; DAMPs; Immune checkpoint inhibitors; Pattern recognition receptors; Tumor microenvironment.

Figures